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Background
Preoperative chemoradiotherapy (CRT) has been widely
adopted as the standard of care for locally advanced rectal
cancer in most western countries. However there has been
a general exclusion of the elderly patients from neoadju-
vant trials often due to concerns over their tolerance of
surgery and/or (chemo)radiotherapy. Our aim was to
compare the compliance to preoperative CRT of rectal
cancer patients aged ≥75 years and younger.
Materials and methods
From March 2002 to October 2008, 132 patients under-
went preoperative long-course radiotherapy (5040 cGy in
28 fractions) with concurrent fluorouracil (FU)-based
chemotherapy for locally advanced (T3–4 and/or N+) or
metastatic (resectable synchronous liver only or lung only
metastases) rectal cancer at Bologna University Hospital.
Chemotherapy was delivered according to one of the fol-
lowing regimens: 1) continuous infusion i.v. of 5-FU
alone (225 mg/m2/day); 2) continuous infusion i.v. of 5-
FU (225 mg/m2/day) plus a weekly bolus of oxaliplatin
60 mg/m2 for 6 times and 3) oral capecitabine (1300 mg/
m2/day). Out of 132 patients, 17 were characterised by
aged 75 or older, Karnofsky performance scale ≥70,
absence of significant comorbidities and comprise the
elderly group. The Fisher's exact test was used to compare
proportions and the Mann-Whitney U test to compare
continuous variables.
Results
Planned radiation therapy was completely delivered in 15
of 17 patients (88 percent) of the older age group and in
106 of 115 (92 percent) of the younger age group (p >
0.05). In only one patient (aged 74 years) radiotherapy
was early (1800 cGy) interrupted because of bowel
obstruction. The full protocol dose of chemotherapy was
delivered in 10 (59%) and 94 (82%) patients of older and
younger age group respectively (p = 0.0514). The main
causes of chemotherapeutic schedule violation in the
older age group were GR3/4 diarrhoea (2 patients), GR3
neutropenia (2 patients), acute neurotoxicity (1 patient),
heart complication (1 patients) and Jacksonian epilepsy
(1 patient). However none of these seven patients
received less than eighty percent of total dose planned. All
older patients underwent surgical treatment seven to eight
weeks after CRT as follow: low anterior resection (10
patients), abdominoperineal resection (5 patients) and
transanal excision (2 patients).
Conclusion
Our results are consistent with the concept that age should
not be the only deciding factor in the treatment of
advanced rectal cancer. As International Society of Geriat-
ric Oncology recommendations, patients should receive
the most intensive and appropriate treatment thought to
be safe and effective according to their biological age and
comorbidities.
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